Eton Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Eton Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
1.6×Over the last 3 years its own operating cash covered its investment spending (capex) 1.6 times.
Higher than 72% of Healthcare companies in United States.
Cash Locked Ratio
$20For every $100 of sales, $20 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $3 tied up three years earlier.
Less money tied up than 57% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 1/3Sales grew in 3 of the last 3 years; profit grew in 1 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
$8Sales grew 276% in 3 years; of every extra $100 of sales, $8 became extra profit.
Lower than 59% of Healthcare companies in United States.
Asset Productivity Ratio
+276% / +268%In 3 years sales changed by +276% while total assets changed by +268%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
1.2×Debt due within a year is covered 1.2 times by its yearly operating cash.
Higher than 72% of Healthcare companies in United States.
Cash Cushion Ratio
−0%Debt, after subtracting cash, equals 0% of its market value (net debt).
Lower than 68% of Healthcare companies in United States.
Tangible Assets Ratio
66%Of every $100 the company owns, $66 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 65% of Healthcare companies in United States.
Tangible Net Worth Ratio
NegativeGoodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative.
Less tangible than 79% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Eton Pharmaceuticals, Inc. owes $0.60 for every $1 it owns. Eton Pharmaceuticals, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
125.0Investors pay $125.0 for every $1 of Eton Pharmaceuticals, Inc.'s yearly profit, higher than 93% of Healthcare companies in United States.
P/B ratio
30.68The share price is 30.68 times Eton Pharmaceuticals, Inc.'s book value per share, higher than 96% of Healthcare companies in United States.
Market cap
$1.4 BThe total market value of all of Eton Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), larger than 69% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$47 MWhat Eton Pharmaceuticals, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.63Net worth divided by the number of shares. The share price of $50.00 is 30.7 times this, which is the P/B above.
Return on equity (ROE)
36.0%Eton Pharmaceuticals, Inc. earned 36.0% on its shareholders' money over the last year, higher than 95% of Healthcare companies in United States.
Owes vs Owns
0.60×Eton Pharmaceuticals, Inc. owes $0.60 for every $1 it owns (moderate), higher than 64% of Healthcare companies in United States.
Dividend yield
NoneEton Pharmaceuticals, Inc. does not currently pay a dividend.
Revenue growth
+105%Revenue rose 105% in the year to Dec 2025, and grew 56% a year on average over 3 years.
Profit growth
LossEton Pharmaceuticals, Inc. made a loss in each of the last two years.
Profit margin
-5.8%Eton Pharmaceuticals, Inc. lost $6 for every $100 of revenue.
Cash vs debt
Net debtEton Pharmaceuticals, Inc. had $5 M more debt than cash (net debt) at Dec 2025.
Questions
What is Eton Pharmaceuticals, Inc.'s P/E ratio?
Investors pay $125.0 for every $1 of Eton Pharmaceuticals, Inc.'s yearly profit, higher than 93% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Eton Pharmaceuticals, Inc.: $1.4 B ÷ $47 M (30 Jun 2026) = 30.7.
What is Eton Pharmaceuticals, Inc.'s return on equity?
Eton Pharmaceuticals, Inc. earned 36.0% on its shareholders' money over the last year, higher than 95% of Healthcare companies in United States.
How much does Eton Pharmaceuticals, Inc. owe compared with what it owns?
Eton Pharmaceuticals, Inc. owes $0.60 for every $1 it owns (moderate), higher than 64% of Healthcare companies in United States.
Does Eton Pharmaceuticals, Inc. pay a dividend?
No. Eton Pharmaceuticals, Inc. does not currently pay a dividend.
Is Eton Pharmaceuticals, Inc.'s revenue growing?
Revenue rose 105% in the year to Dec 2025, and grew 56% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.